Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ophthotech Corp (OPHT)

Ophthotech Corp (OPHT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,577
  • Shares Outstanding, K 41,422
  • Annual Sales, $ 0 K
  • Annual Income, $ 63,090 K
  • 60-Month Beta 1.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.46
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.31
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/08/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Sell
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.36
  • Number of Estimates 1
  • High Estimate -0.36
  • Low Estimate -0.36
  • Prior Year -0.36
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.38 +0.72%
on 04/12/19
1.60 -13.13%
on 03/19/19
-0.17 (-10.90%)
since 03/15/19
3-Month
1.21 +14.88%
on 02/05/19
1.63 -14.72%
on 03/05/19
unch (unch)
since 01/16/19
52-Week
1.02 +36.27%
on 12/27/18
4.50 -69.11%
on 06/07/18
-1.29 (-48.13%)
since 04/16/18

Most Recent Stories

More News
Companies Strive to Tackle Ocular Diseases as Rates of Incidences Grow

There is an alarming increase in the frequency of eye-related diseases, particularly in developed countries, which in turn is expected to drive the growth of the global retinal drugs market. There are...

OPHT : 1.39 (-0.71%)
AMBS : 0.0152 (-1.94%)
AGTC : 2.69 (-0.74%)
ISEE : 6.34 (+12.41%)
EYEN : 3.34 (-2.34%)
IRIX : 2.39 (-4.63%)
Ophthotech Transitions to a Gene Therapy Focused Company Developing Treatments for Orphan Inherited Retinal Diseases and Changes Name to IVERIC bio

Ophthotech Corporation (Nasdaq:OPHT) today announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited...

OPHT : 1.39 (-0.71%)
New Research: Key Drivers of Growth for Cinemark, Omega Healthcare Investors, PDC Energy, LiveXLive Media, Ophthotech, and Howard Hughes -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cinemark Holdings Inc (NYSE:CNK),...

CNK : 34.71 (+1.73%)
OHI : 41.42 (-1.66%)
PDCE : 23.54 (+1.64%)
LIVX : 2.22 (-5.13%)
OPHT : 1.39 (-0.71%)
HHC : 115.41 (-0.03%)
Ophthotech Gets Rights to Gene Therapy for BEST Disease

Ophthotech (OPHT) obtains development/commercialization rights to AAV gene-therapy program for BEST1-related retinal diseases from Penn and UFRF.

RHHBY : 38.4400 (-0.13%)
NVS : 93.06 (+0.02%)
ONCE : 110.55 (-0.32%)
OPHT : 1.39 (-0.71%)
Ophthotech Obtains Exclusive Global License to AAV Gene Therapy Program for BEST1 Related Retinal Diseases

Ophthotech Corporation (NASDAQ: OPHT) announced today that the Company has converted its option and entered into an exclusive global license agreement with the University of Pennsylvania...

OPHT : 1.39 (-0.71%)
4 Gene Therapy Players Likely to Become Buyout Targets in 2019

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

OPHT : 1.39 (-0.71%)
QURE : 68.88 (+5.27%)
ONCE : 110.55 (-0.32%)
RGNX : 42.01 (+3.81%)
SRPT : 100.47 (-0.97%)
NITE : 25.41 (-0.04%)
BOLD : 59.37 (-0.12%)
SLDB : 4.26 (+3.40%)
Ophthotech (OPHT) Down 2.1% Since Last Earnings Report: Can It Rebound?

Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

OPHT : 1.39 (-0.71%)
Ophthotech to Present at the Alliance for Regenerative Medicine's (ARM) 7th Annual Cell & Gene Therapy Investor Day

Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer, will present an overview of the Company at the Alliance for Regenerative...

OPHT : 1.39 (-0.71%)
Ophthotech to Present at the Cowen and Company 39th Annual Health Care Conference

Ophthotech Corporation (Nasdaq: OPHT) announced today that Kourous A. Rezaei, M.D., Chief Medical Officer of Ophthotech, will present an overview of the Company at the Cowen and Company...

OPHT : 1.39 (-0.71%)
Ophthotech's (OPHT) Q4 Loss Wider, Gene Therapy in Focus

Ophthotech (OPHT) reports wider-than-expected loss in the fourth quarter. It boosts gene therapy pipeline through new agreements and acquisitions.

RHHBY : 38.4400 (-0.13%)
NVS : 93.06 (+0.02%)
NVO : 56.50 (-0.63%)
OPHT : 1.39 (-0.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade OPHT with:

Business Summary

Ophthotech Corporation is a biopharmaceutical company. It is focused on developing and commercializing novel therapies for the treatment of diseases of the eye. The Company is developing Fovista and ARC1905, which are under clinical trials, for the treatment of wet AMD. Ophthotech Corporation is headquartered...

See More

Key Turning Points

2nd Resistance Point 1.51
1st Resistance Point 1.45
Last Price 1.39
1st Support Level 1.36
2nd Support Level 1.33

See More

52-Week High 4.50
Fibonacci 61.8% 3.17
Fibonacci 50% 2.76
Fibonacci 38.2% 2.35
Last Price 1.39
52-Week Low 1.02

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar